Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1986-02

AUTHORS

J B Vermorken, W J van der Vijgh, I Klein, H E Gall, C J van Groeningen, G A Hart, H M Pinedo

ABSTRACT

Pharmacokinetic studies were performed in 51 patients who received cisplatin infusions. Two treatment regimens (single-day or daily for 5 days) and three infusion schedules (for 4 to 15 minutes, 2 to 3 hours, or 24 hours) were used. The daily dose of cisplatin varied from 20 to 120 mg/m2. The kinetics of total platinum studied up to day 5 revealed differences only during the initial period after the infusion. Peak levels were both dose and schedule dependent and initial t1/2 values in the decay curves were only schedule dependent (mean values: 13 minutes for rapid infusions, 40.3 minutes for 2 to 3-hour infusions, and 220.5 minutes for 24-hour infusion). The t1/2 values between days 1 and 5 were neither dose nor schedule dependent (mean 5.0 to 7.3 days). Concentrations of free platinum declined biexponentially after the rapid and 2 to 3-hour infusions, but they declined monoexponentially after 24-hour infusions. Final t1/2 values ranged from 26.0 to 78.8 minutes. In patients with normal renal and hepatic function, the free platinum AUC was identical for cisplatin infusions of different duration when equal doses were given. Free platinum clearance correlated with creatinine clearance (P = 0.017). The uptake of platinum in red blood cells was rapid, and peak concentrations correlated with the free platinum AUC (P = 0.0006), independent of the infusion schedule. The decay of platinum levels in red blood cells was biphasic. The mean terminal t1/2 for the interval between days 5 and 15 was 29.8 days. This suggests a breakdown of red blood cells that results from cisplatin dosing. More... »

PAGES

136-144

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/clpt.1986.24

DOI

http://dx.doi.org/10.1038/clpt.1986.24

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1028394753

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/3943271


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Erythrocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Half-Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Parenteral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kinetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platinum", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pleural Effusion", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "familyName": "Vermorken", 
        "givenName": "J B", 
        "id": "sg:person.0653351227.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653351227.67"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "van der Vijgh", 
        "givenName": "W J", 
        "id": "sg:person.01336673634.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336673634.28"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Klein", 
        "givenName": "I", 
        "id": "sg:person.01364113773.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364113773.14"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Gall", 
        "givenName": "H E", 
        "id": "sg:person.01023051473.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023051473.48"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "van Groeningen", 
        "givenName": "C J", 
        "id": "sg:person.01072777672.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072777672.33"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Hart", 
        "givenName": "G A", 
        "type": "Person"
      }, 
      {
        "familyName": "Pinedo", 
        "givenName": "H M", 
        "id": "sg:person.013437631522.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013437631522.70"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1986-02", 
    "datePublishedReg": "1986-02-01", 
    "description": "Pharmacokinetic studies were performed in 51 patients who received cisplatin infusions. Two treatment regimens (single-day or daily for 5 days) and three infusion schedules (for 4 to 15 minutes, 2 to 3 hours, or 24 hours) were used. The daily dose of cisplatin varied from 20 to 120 mg/m2. The kinetics of total platinum studied up to day 5 revealed differences only during the initial period after the infusion. Peak levels were both dose and schedule dependent and initial t1/2 values in the decay curves were only schedule dependent (mean values: 13 minutes for rapid infusions, 40.3 minutes for 2 to 3-hour infusions, and 220.5 minutes for 24-hour infusion). The t1/2 values between days 1 and 5 were neither dose nor schedule dependent (mean 5.0 to 7.3 days). Concentrations of free platinum declined biexponentially after the rapid and 2 to 3-hour infusions, but they declined monoexponentially after 24-hour infusions. Final t1/2 values ranged from 26.0 to 78.8 minutes. In patients with normal renal and hepatic function, the free platinum AUC was identical for cisplatin infusions of different duration when equal doses were given. Free platinum clearance correlated with creatinine clearance (P = 0.017). The uptake of platinum in red blood cells was rapid, and peak concentrations correlated with the free platinum AUC (P = 0.0006), independent of the infusion schedule. The decay of platinum levels in red blood cells was biphasic. The mean terminal t1/2 for the interval between days 5 and 15 was 29.8 days. This suggests a breakdown of red blood cells that results from cisplatin dosing.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/clpt.1986.24", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017409", 
        "issn": [
          "0009-9236", 
          "1532-6535"
        ], 
        "name": "Clinical Pharmacology & Therapeutics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "name": "Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin", 
    "pagination": "136-144", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "874446e53d06e91c961483841eda2b8020b27dc809b73de1a5d1215f4c99dff7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "3943271"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0372741"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/clpt.1986.24"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1028394753"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/clpt.1986.24", 
      "https://app.dimensions.ai/details/publication/pub.1028394753"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T22:51", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8693_00000048.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://onlinelibrary.wiley.com/doi/10.1038/clpt.1986.24/abstract"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/clpt.1986.24'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/clpt.1986.24'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/clpt.1986.24'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/clpt.1986.24'


 

This table displays all metadata directly associated to this object as RDF triples.

164 TRIPLES      20 PREDICATES      45 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/clpt.1986.24 schema:about N03327497c1094ecf86a640e5fd62f03e
2 N243a1cb1672a49e89dfa2418c428be6c
3 N3558a332847049f0a836285bcd35bb11
4 N39380fbf348847798dd0812a370d47e3
5 N42989f95877840cd86698da59cbc6c88
6 N808cf2e4d61e4ad39573d6155001a25c
7 N8c13832bf3f0400b9d96de2e686da4ce
8 N94d81572e3f5492a8cdeaf5b33ad8e4b
9 N9f96080b87e940a79da1d20faad2fb1e
10 Na319d32ecd4844b2bd9f6a7d57890140
11 Nabbcac20d9084f8389cc36e614305e77
12 Ncd89eb4056ac4451a025ac5ce504be29
13 Nd02cfb79c3c3464e8b54d4cecac309ee
14 Nd111bc5cad7d4f30be8a3885b9decde1
15 Ndb7cb80b2ba4490ab7b2dbc81fb469d0
16 Nfa431bad36164e4680e21c95fd336133
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N7724654033ed48a7871f49b41175be30
20 schema:datePublished 1986-02
21 schema:datePublishedReg 1986-02-01
22 schema:description Pharmacokinetic studies were performed in 51 patients who received cisplatin infusions. Two treatment regimens (single-day or daily for 5 days) and three infusion schedules (for 4 to 15 minutes, 2 to 3 hours, or 24 hours) were used. The daily dose of cisplatin varied from 20 to 120 mg/m2. The kinetics of total platinum studied up to day 5 revealed differences only during the initial period after the infusion. Peak levels were both dose and schedule dependent and initial t1/2 values in the decay curves were only schedule dependent (mean values: 13 minutes for rapid infusions, 40.3 minutes for 2 to 3-hour infusions, and 220.5 minutes for 24-hour infusion). The t1/2 values between days 1 and 5 were neither dose nor schedule dependent (mean 5.0 to 7.3 days). Concentrations of free platinum declined biexponentially after the rapid and 2 to 3-hour infusions, but they declined monoexponentially after 24-hour infusions. Final t1/2 values ranged from 26.0 to 78.8 minutes. In patients with normal renal and hepatic function, the free platinum AUC was identical for cisplatin infusions of different duration when equal doses were given. Free platinum clearance correlated with creatinine clearance (P = 0.017). The uptake of platinum in red blood cells was rapid, and peak concentrations correlated with the free platinum AUC (P = 0.0006), independent of the infusion schedule. The decay of platinum levels in red blood cells was biphasic. The mean terminal t1/2 for the interval between days 5 and 15 was 29.8 days. This suggests a breakdown of red blood cells that results from cisplatin dosing.
23 schema:genre research_article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf Nc568bd474a684bca820a204a2a1c48e6
27 Nd60a401908874fccaef7d4dbd458a4e7
28 sg:journal.1017409
29 schema:name Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin
30 schema:pagination 136-144
31 schema:productId N1a0cf18bdd684230898ac248bb469b06
32 N1e7b65f851bc4c2386ada40d068c5d6b
33 N55ba404ecbdf43cd8cc780a74bab0558
34 Ncd413f802f0245b5b57ecde568d8e158
35 Nfe65cb4387fd49c7aa2bc9b61b024292
36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028394753
37 https://doi.org/10.1038/clpt.1986.24
38 schema:sdDatePublished 2019-04-10T22:51
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher N16c288841b3d4650adfa2fa18ed89ca7
41 schema:url http://onlinelibrary.wiley.com/doi/10.1038/clpt.1986.24/abstract
42 sgo:license sg:explorer/license/
43 sgo:sdDataset articles
44 rdf:type schema:ScholarlyArticle
45 N03327497c1094ecf86a640e5fd62f03e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
46 schema:name Aged
47 rdf:type schema:DefinedTerm
48 N14dd6886c6d24f82bf978e91a3f4a5c0 schema:familyName Hart
49 schema:givenName G A
50 rdf:type schema:Person
51 N16c288841b3d4650adfa2fa18ed89ca7 schema:name Springer Nature - SN SciGraph project
52 rdf:type schema:Organization
53 N1a0cf18bdd684230898ac248bb469b06 schema:name readcube_id
54 schema:value 874446e53d06e91c961483841eda2b8020b27dc809b73de1a5d1215f4c99dff7
55 rdf:type schema:PropertyValue
56 N1e7b65f851bc4c2386ada40d068c5d6b schema:name doi
57 schema:value 10.1038/clpt.1986.24
58 rdf:type schema:PropertyValue
59 N243a1cb1672a49e89dfa2418c428be6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Middle Aged
61 rdf:type schema:DefinedTerm
62 N3558a332847049f0a836285bcd35bb11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Platinum
64 rdf:type schema:DefinedTerm
65 N39380fbf348847798dd0812a370d47e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Half-Life
67 rdf:type schema:DefinedTerm
68 N3b603b752e5a4d65b50569a563ee96d4 rdf:first sg:person.01336673634.28
69 rdf:rest Nf4d72df7b60e4c03b1cc076c063205e5
70 N42989f95877840cd86698da59cbc6c88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Infusions, Parenteral
72 rdf:type schema:DefinedTerm
73 N45859026ac7e4527aa9407e0cb36801a rdf:first sg:person.01023051473.48
74 rdf:rest Na04815131141436fa1895b3d62c5e08f
75 N55ba404ecbdf43cd8cc780a74bab0558 schema:name pubmed_id
76 schema:value 3943271
77 rdf:type schema:PropertyValue
78 N63c67e7bbf2143bfb490ace0f2679f11 rdf:first N14dd6886c6d24f82bf978e91a3f4a5c0
79 rdf:rest Nae5710d883954b7d8d9a91d64e8f705e
80 N7724654033ed48a7871f49b41175be30 rdf:first sg:person.0653351227.67
81 rdf:rest N3b603b752e5a4d65b50569a563ee96d4
82 N808cf2e4d61e4ad39573d6155001a25c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Liver
84 rdf:type schema:DefinedTerm
85 N8c13832bf3f0400b9d96de2e686da4ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Humans
87 rdf:type schema:DefinedTerm
88 N94d81572e3f5492a8cdeaf5b33ad8e4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Pleural Effusion
90 rdf:type schema:DefinedTerm
91 N9f96080b87e940a79da1d20faad2fb1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Drug Therapy, Combination
93 rdf:type schema:DefinedTerm
94 Na04815131141436fa1895b3d62c5e08f rdf:first sg:person.01072777672.33
95 rdf:rest N63c67e7bbf2143bfb490ace0f2679f11
96 Na319d32ecd4844b2bd9f6a7d57890140 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Cisplatin
98 rdf:type schema:DefinedTerm
99 Nabbcac20d9084f8389cc36e614305e77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Adult
101 rdf:type schema:DefinedTerm
102 Nae5710d883954b7d8d9a91d64e8f705e rdf:first sg:person.013437631522.70
103 rdf:rest rdf:nil
104 Nc568bd474a684bca820a204a2a1c48e6 schema:volumeNumber 39
105 rdf:type schema:PublicationVolume
106 Ncd413f802f0245b5b57ecde568d8e158 schema:name nlm_unique_id
107 schema:value 0372741
108 rdf:type schema:PropertyValue
109 Ncd89eb4056ac4451a025ac5ce504be29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Drug Administration Schedule
111 rdf:type schema:DefinedTerm
112 Nd02cfb79c3c3464e8b54d4cecac309ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Erythrocytes
114 rdf:type schema:DefinedTerm
115 Nd111bc5cad7d4f30be8a3885b9decde1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Kidney
117 rdf:type schema:DefinedTerm
118 Nd60a401908874fccaef7d4dbd458a4e7 schema:issueNumber 2
119 rdf:type schema:PublicationIssue
120 Ndb7cb80b2ba4490ab7b2dbc81fb469d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Kinetics
122 rdf:type schema:DefinedTerm
123 Nf4d72df7b60e4c03b1cc076c063205e5 rdf:first sg:person.01364113773.14
124 rdf:rest N45859026ac7e4527aa9407e0cb36801a
125 Nfa431bad36164e4680e21c95fd336133 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Neoplasms
127 rdf:type schema:DefinedTerm
128 Nfe65cb4387fd49c7aa2bc9b61b024292 schema:name dimensions_id
129 schema:value pub.1028394753
130 rdf:type schema:PropertyValue
131 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
132 schema:name Medical and Health Sciences
133 rdf:type schema:DefinedTerm
134 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
135 schema:name Clinical Sciences
136 rdf:type schema:DefinedTerm
137 sg:journal.1017409 schema:issn 0009-9236
138 1532-6535
139 schema:name Clinical Pharmacology & Therapeutics
140 rdf:type schema:Periodical
141 sg:person.01023051473.48 schema:familyName Gall
142 schema:givenName H E
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023051473.48
144 rdf:type schema:Person
145 sg:person.01072777672.33 schema:familyName van Groeningen
146 schema:givenName C J
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072777672.33
148 rdf:type schema:Person
149 sg:person.01336673634.28 schema:familyName van der Vijgh
150 schema:givenName W J
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336673634.28
152 rdf:type schema:Person
153 sg:person.013437631522.70 schema:familyName Pinedo
154 schema:givenName H M
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013437631522.70
156 rdf:type schema:Person
157 sg:person.01364113773.14 schema:familyName Klein
158 schema:givenName I
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364113773.14
160 rdf:type schema:Person
161 sg:person.0653351227.67 schema:familyName Vermorken
162 schema:givenName J B
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653351227.67
164 rdf:type schema:Person
 




Preview window. Press ESC to close (or click here)


...